Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.53 |
| ▸ | DGAT1 | O75907 | 3/20 | 0.36 |
| ▸ | AKT1 | P31749 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | KCNN3 | Q9UGI6 | 4/20 | 0.33 |
| ▸ | KCNN1 | Q92952 | 1/20 | 0.33 |
| ▸ | KCNN2 | Q9H2S1 | 1/20 | 0.33 |
| ▸ | EGLN2 | Q96KS0 | 3/20 | 0.32 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10407034 | 0.73 | PDE10A (0.35) | PDE10ADGAT1EGLN2MKNK1 | |
| SCHEMBL21138821 | 0.73 | DGAT1 (0.42) | PDE10ADGAT1EGLN2MKNK1 | |
| SCHEMBL2991637 | 0.73 | PDE10A (0.35) | PDE10ADGAT1EGLN2MKNK1 | |
| SCHEMBL30537 | 0.73 | DGAT1 (0.42) | PDE10ADGAT1AKT1EGLN2MKNK1 | |
| SCHEMBL4572140 | 0.73 | DGAT1 (0.37) | PDE10ADGAT1EGLN2MKNK1 | |
| SCHEMBL30786518 | 0.71 | PDE10A (0.34) | PDE10ADGAT1AKT1EGLN2MKNK1 | |
| SCHEMBL14649428 | 0.71 | PDE10A (0.42) | PDE10ADGAT1KCNN3KCNN1KCNN2 | |
| SCHEMBL5946425 | 0.69 | CYP2A6 (0.41) | PDE10ADGAT1EGLN2MKNK1 | |
| SCHEMBL23529925 | 0.68 | DGAT1 (0.36) | PDE10ADGAT1AKT1 | |
| SCHEMBL6025895 | 0.68 | DGAT1 (0.34) | PDE10ADGAT1KCNN3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 229 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119350343-A | Synthesis method of 7-chloropyrazolo [1,5-a ] pyrimidine | 凯美克(上海)医药科技有限公司 | 2025-01-24 | — | — | CN | claimed |
| US-12522595-B2 | Bicyclic ether O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitors | BIOGEN MA INC. (US) | 2026-01-13 | — | — | US | disclosed |
| US-20250275965-A1 | COMPOUNDS AS CASEIN KINASE INHIBITORS | GRITSCIENCE BIOPHARMACEUTICALS CO LTD (CN) | 2025-09-04 | — | — | US | disclosed |
| EP-4051680-B1 | CONDENSED BI-HETEROCYCLES AS INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | BIOGEN MA INC (US) | 2025-09-03 | — | — | EP | disclosed |
| EP-4568951-A1 | HETEROCYCLIC AMIDE AND UREA COMPOUNDS AS JAK2 INHIBITORS | AJAX THERAPEUTICS, INC. (US) | 2025-06-18 | — | — | EP | disclosed |
| CN-119899187-A | Synthesis method of pyrazolo [1,5-a ] pyrimidine-7-amine compound | 湖南九典制药股份有限公司 | 2025-04-29 | — | — | CN | disclosed |
| CN-119654314-A | Heterocyclic amide and urea compounds as JAK2 inhibitors | 艾捷斯治疗公司 | 2025-03-18 | — | — | CN | disclosed |
| CN-119350343-A | Synthesis method of 7-chloropyrazolo [1,5-a ] pyrimidine | 凯美克(上海)医药科技有限公司 | 2025-01-24 | — | — | CN | disclosed |
| CN-119350343-A | Synthesis method of 7-chloropyrazolo [1,5-a ] pyrimidine | 凯美克(上海)医药科技有限公司 | 2025-01-24 | — | — | CN | disclosed |
| CN-119350343-A | Synthesis method of 7-chloropyrazolo [1,5-a ] pyrimidine | 凯美克(上海)医药科技有限公司 | 2025-01-24 | — | — | CN | disclosed |
| WO-2005103052-A1 | PYRAZOLO [1,5-A] PYRIMIDIN-7-ONE COMPOUNDS AND USES THEREOF | PFIZER PRODUCTS INC. (US) | 2005-11-03 | — | — | WO | disclosed |
| EP-1511751-A1 | PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS ANTIVIRAL AGENTS | Neogenesis Pharmaceuticals, Inc. (US) | 2005-03-09 | — | — | EP | disclosed |
| WO-2004087707-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN MEDICINE | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2004-10-14 | — | — | WO | disclosed |
| WO-2004069838-A1 | CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | PFIZER PRODUCTS INC. (US) | 2004-08-19 | — | — | WO | disclosed |
| US-20040157838-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC | 2004-08-12 | — | — | US | disclosed |
| US-20040038993-A1 | Pyrazolo[1,5a]pyrimidine compounds as antiviral agents | NEOGENESIS PHARMACEUTICALS, INC. | 2004-02-26 | — | — | US | disclosed |
| WO-2003101993-A1 | PYRAZOLO` 1,5A! PYRIMIDINE COMPOUNDS AS ANTIVIRAL AGENTS | NEOGENESIS PHARMACEUTICALS, INC. (US) | 2003-12-11 | — | — | WO | disclosed |
| EP-0591528-B1 | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVE AND ANTI-INFLAMMATORY CONTAINING THE SAME | OTSUKA PHARMA CO LTD (JP) | 1998-12-23 | — | — | EP | disclosed |
| US-5688949-A | CYCLOOXYGENASE INHIBITORS | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 1997-11-18 | — | — | US | disclosed |
| EP-0591528-A1 | PYRAZOLO 1,5-a]PYRIMIDINE DERIVATIVE AND ANTI-INFLAMMATORY CONTAINING THE SAME | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 1994-04-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157838-A1 | Cannabinoid receptor ligands and uses thereof | CNR1, CNR2, GPR18 | PDE10A 2451/4885DGAT1 590/4885AKT1 2736/4885 |
| US-20040038993-A1 | Pyrazolo[1,5a]pyrimidine compounds as antiviral agents | RNGTT, PNP, ZC3HAV1 | PDE10A 2150/4885DGAT1 1744/4885AKT1 3986/4885 |
| US-20250275965-A1 | COMPOUNDS AS CASEIN KINASE INHIBITORS | PACSIN2, CSNK1A1, CSNK1G3 | PDE10A 3062/4885DGAT1 3055/4885AKT1 458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.